PMID- 27520400
OWN - NLM
STAT- MEDLINE
DCOM- 20171219
LR  - 20181202
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Linking)
VI  - 111
DP  - 2016 Sep
TI  - Six months of resveratrol supplementation has no measurable effect in type 2 
      diabetic patients. A randomized, double blind, placebo-controlled trial.
PG  - 896-905
LID - S1043-6618(16)30620-X [pii]
LID - 10.1016/j.phrs.2016.08.010 [doi]
AB  - The polyphenol resveratrol is considered to exert many beneficial actions, such 
      as antioxidant, anti-inflammatory, insulin-sensitizer and anticancer effects. Its 
      benefits in patients with type 2 diabetes mellitus (T2DM) are controversial. Our 
      aims were to determine whether resveratrol supplementation at two different 
      dosages (500 and 40mg/day) for 6 months i) reduced the concentrations of 
      C-reactive-protein (CRP) and ii) ameliorated the metabolic pattern of T2DM 
      patients. In the present double-blind, randomized, placebo-controlled trial, 192 
      T2DM patients were randomized to receive resveratrol 500mg/day (Resv500arm), 
      resveratrol 40mg/day (Resv40arm) or placebo for 6-months. At baseline and at the 
      trial end, CRP values, anthropometric, metabolic and liver parameters were 
      determined. No serious adverse event occurred. A dose-dependent, though not 
      significant, CRP decrease of 5.6% (Resv40arm) and 15.9% (Resv500arm) was observed 
      vs placebo. We failed to detect significant differences in weight, BMI, waist 
      circumference, and values of arterial blood pressure, fasting glucose, glycated 
      hemoglobin, insulin, C-peptide, free fatty acids, liver transaminases, uric acid, 
      adiponectin, interleukin-6, in both the Resv500 and Resv40 arms vs placebo. Total 
      cholesterol and triglycerides slightly increased in the Resv500arm. Subgroup 
      analyses revealed that lower diabetes duration (in both Resv500 and Resv40arms), 
      and, in the Resv500arm, younger age, aspirin use and being a smoker were 
      associated with a significantly higher CRP reduction vs placebo. The 
      supplementations with 40mg/day or 500mg/day resveratrol did neither reduce CRP 
      concentrations, nor improve the metabolic pattern of T2DM patients.
CI  - Copyright (c) 2016 Elsevier Ltd. All rights reserved.
FAU - Bo, S
AU  - Bo S
AD  - Department of Medical Sciences, University of Turin, Turin, Italy. Electronic 
      address: simona.bo@unito.it.
FAU - Ponzo, V
AU  - Ponzo V
AD  - Department of Medical Sciences, University of Turin, Turin, Italy.
FAU - Ciccone, G
AU  - Ciccone G
AD  - Unit of Clinical Epidemiology, CPO, Citta della Salute e della Scienza, Hospital 
      of Turin, Turin, Italy.
FAU - Evangelista, A
AU  - Evangelista A
AD  - Unit of Clinical Epidemiology, CPO, Citta della Salute e della Scienza, Hospital 
      of Turin, Turin, Italy.
FAU - Saba, F
AU  - Saba F
AD  - Department of Medical Sciences, University of Turin, Turin, Italy.
FAU - Goitre, I
AU  - Goitre I
AD  - Department of Medical Sciences, University of Turin, Turin, Italy.
FAU - Procopio, M
AU  - Procopio M
AD  - Department of Medical Sciences, University of Turin, Turin, Italy.
FAU - Pagano, G F
AU  - Pagano GF
AD  - Department of Medical Sciences, University of Turin, Turin, Italy.
FAU - Cassader, M
AU  - Cassader M
AD  - Department of Medical Sciences, University of Turin, Turin, Italy.
FAU - Gambino, R
AU  - Gambino R
AD  - Department of Medical Sciences, University of Turin, Turin, Italy.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160809
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - 0 (Biomarkers)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Stilbenes)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Biomarkers/blood
MH  - C-Reactive Protein/metabolism
MH  - Diabetes Mellitus, Type 2/blood/diagnosis/*drug therapy/physiopathology
MH  - *Dietary Supplements/adverse effects
MH  - Double-Blind Method
MH  - Health Status
MH  - Humans
MH  - Inflammation Mediators/blood
MH  - Italy
MH  - Resveratrol
MH  - Stilbenes/*administration & dosage/adverse effects
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - C-reactive protein
OT  - Resveratrol
OT  - Resveratrol (PubChem CID: 445154)
OT  - Type 2 diabetes mellitus
EDAT- 2016/08/16 06:00
MHDA- 2017/12/20 06:00
CRDT- 2016/08/14 06:00
PHST- 2016/06/28 00:00 [received]
PHST- 2016/08/03 00:00 [revised]
PHST- 2016/08/08 00:00 [accepted]
PHST- 2016/08/14 06:00 [entrez]
PHST- 2016/08/16 06:00 [pubmed]
PHST- 2017/12/20 06:00 [medline]
AID - S1043-6618(16)30620-X [pii]
AID - 10.1016/j.phrs.2016.08.010 [doi]
PST - ppublish
SO  - Pharmacol Res. 2016 Sep;111:896-905. doi: 10.1016/j.phrs.2016.08.010. Epub 2016 
      Aug 9.